SURGERY PARTNERS INC (SGRY) Fundamental Analysis & Valuation

NASDAQ:SGRY • US86881A1007

Current stock price

14.27 USD
+0.24 (+1.71%)
At close:
14.1 USD
-0.17 (-1.19%)
After Hours:

This SGRY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. SGRY Profitability Analysis

1.1 Basic Checks

  • In the past year SGRY was profitable.
  • SGRY had a positive operating cash flow in the past year.
  • In the past 5 years SGRY always reported negative net income.
  • In the past 5 years SGRY always reported a positive cash flow from operatings.
SGRY Yearly Net Income VS EBIT VS OCF VS FCFSGRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • SGRY has a Return On Assets (-0.96%) which is in line with its industry peers.
  • SGRY has a Return On Equity of -4.55%. This is comparable to the rest of the industry: SGRY outperforms 46.53% of its industry peers.
  • SGRY has a Return On Invested Capital of 5.05%. This is comparable to the rest of the industry: SGRY outperforms 58.42% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 8.40%.
Industry RankSector Rank
ROA -0.96%
ROE -4.55%
ROIC 5.05%
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
SGRY Yearly ROA, ROE, ROICSGRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

1.3 Margins

  • SGRY's Operating Margin of 14.49% is amongst the best of the industry. SGRY outperforms 89.11% of its industry peers.
  • In the last couple of years the Operating Margin of SGRY has grown nicely.
  • Looking at the Gross Margin, with a value of 25.78%, SGRY is in line with its industry, outperforming 55.45% of the companies in the same industry.
  • SGRY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.49%
PM (TTM) N/A
GM 25.78%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
SGRY Yearly Profit, Operating, Gross MarginsSGRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SGRY Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SGRY is destroying value.
  • The number of shares outstanding for SGRY has been increased compared to 1 year ago.
  • Compared to 5 years ago, SGRY has more shares outstanding
  • SGRY has a worse debt/assets ratio than last year.
SGRY Yearly Shares OutstandingSGRY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SGRY Yearly Total Debt VS Total AssetsSGRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • Based on the Altman-Z score of 0.71, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
  • SGRY's Altman-Z score of 0.71 is on the low side compared to the rest of the industry. SGRY is outperformed by 71.29% of its industry peers.
  • The Debt to FCF ratio of SGRY is 18.93, which is on the high side as it means it would take SGRY, 18.93 years of fcf income to pay off all of its debts.
  • SGRY has a worse Debt to FCF ratio (18.93) than 64.36% of its industry peers.
  • A Debt/Equity ratio of 2.10 is on the high side and indicates that SGRY has dependencies on debt financing.
  • SGRY has a worse Debt to Equity ratio (2.10) than 74.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 18.93
Altman-Z 0.71
ROIC/WACC0.55
WACC9.19%
SGRY Yearly LT Debt VS Equity VS FCFSGRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • SGRY has a Current Ratio of 1.87. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
  • SGRY has a better Current ratio (1.87) than 77.23% of its industry peers.
  • SGRY has a Quick Ratio of 1.71. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.71, SGRY is in the better half of the industry, outperforming 73.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.71
SGRY Yearly Current Assets VS Current LiabilitesSGRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SGRY Growth Analysis

3.1 Past

  • SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.06%.
  • SGRY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 52.38% yearly.
  • SGRY shows a small growth in Revenue. In the last year, the Revenue has grown by 6.24%.
  • SGRY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.21% yearly.
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%

3.2 Future

  • SGRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.17% yearly.
  • Based on estimates for the next years, SGRY will show a quite strong growth in Revenue. The Revenue will grow by 8.28% on average per year.
EPS Next Y-46.78%
EPS Next 2Y-0.67%
EPS Next 3Y12.18%
EPS Next 5Y17.17%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.28%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SGRY Yearly Revenue VS EstimatesSGRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
SGRY Yearly EPS VS EstimatesSGRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

4

4. SGRY Valuation Analysis

4.1 Price/Earnings Ratio

  • SGRY is valuated quite expensively with a Price/Earnings ratio of 31.02.
  • The rest of the industry has a similar Price/Earnings ratio as SGRY.
  • SGRY is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.64, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 58.29, which means the current valuation is very expensive for SGRY.
  • SGRY's Price/Forward Earnings is on the same level as the industry average.
  • SGRY is valuated expensively when we compare the Price/Forward Earnings ratio to 21.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 31.02
Fwd PE 58.29
SGRY Price Earnings VS Forward Price EarningsSGRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • SGRY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SGRY is cheaper than 81.19% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, SGRY is valued cheaper than 84.16% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.44
EV/EBITDA 8.1
SGRY Per share dataSGRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

  • SGRY's earnings are expected to grow with 12.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.67%
EPS Next 3Y12.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGRY Dividend Analysis

5.1 Amount

  • SGRY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SGRY Fundamentals: All Metrics, Ratios and Statistics

SURGERY PARTNERS INC

NASDAQ:SGRY (5/1/2026, 8:00:02 PM)

After market: 14.1 -0.17 (-1.19%)

14.27

+0.24 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Industry Strength60.87
Industry Growth63.98
Earnings (Last)03-02
Earnings (Next)05-05
Inst Owners83.54%
Inst Owner Change-0.32%
Ins Owners1.63%
Ins Owner Change1.19%
Market Cap1.85B
Revenue(TTM)3.31B
Net Income(TTM)-77.90M
Analysts81.11
Price Target19.53 (36.86%)
Short Float %20.58%
Short Ratio10.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.91%
Min EPS beat(2)-60.78%
Max EPS beat(2)-23.03%
EPS beat(4)1
Avg EPS beat(4)-21%
Min EPS beat(4)-60.78%
Max EPS beat(4)24.15%
EPS beat(8)4
Avg EPS beat(8)-6.88%
EPS beat(12)8
Avg EPS beat(12)176.88%
EPS beat(16)9
Avg EPS beat(16)102.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)0.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.14%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)4
Avg Revenue beat(12)-0.76%
Revenue beat(16)6
Avg Revenue beat(16)-0.79%
PT rev (1m)-0.99%
PT rev (3m)-26.35%
EPS NQ rev (1m)-1.45%
EPS NQ rev (3m)-528.27%
EPS NY rev (1m)-67.35%
EPS NY rev (3m)-67.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.21%
Valuation
Industry RankSector Rank
PE 31.02
Fwd PE 58.29
P/S 0.56
P/FCF 9.44
P/OCF 6.73
P/B 1.08
P/tB N/A
EV/EBITDA 8.1
EPS(TTM)0.46
EY3.22%
EPS(NY)0.24
Fwd EY1.72%
FCF(TTM)1.51
FCFY10.59%
OCF(TTM)2.12
OCFY14.85%
SpS25.57
BVpS13.24
TBVpS-27.22
PEG (NY)N/A
PEG (5Y)N/A
Graham Number11.704 (-17.98%)
Profitability
Industry RankSector Rank
ROA -0.96%
ROE -4.55%
ROCE 6.39%
ROIC 5.05%
ROICexc 5.21%
ROICexgc 18.67%
OM 14.49%
PM (TTM) N/A
GM 25.78%
FCFM 5.91%
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
ROICexc(3y)5.3%
ROICexc(5y)5.11%
ROICexgc(3y)19.01%
ROICexgc(5y)18.72%
ROCE(3y)6.48%
ROCE(5y)6.19%
ROICexgc growth 3Y2.9%
ROICexgc growth 5Y5.08%
ROICexc growth 3Y1.35%
ROICexc growth 5Y9.67%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 18.93
Debt/EBITDA 5.5
Cap/Depr 44.72%
Cap/Sales 2.38%
Interest Coverage 1.87
Cash Conversion 41.85%
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.71
Altman-Z 0.71
F-Score5
WACC9.19%
ROIC/WACC0.55
Cap/Depr(3y)59.72%
Cap/Depr(5y)61.53%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-46.78%
EPS Next 2Y-0.67%
EPS Next 3Y12.18%
EPS Next 5Y17.17%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.28%
EBIT growth 1Y1.03%
EBIT growth 3Y8.59%
EBIT growth 5Y20.49%
EBIT Next Year28.56%
EBIT Next 3Y15.28%
EBIT Next 5YN/A
FCF growth 1Y-6.72%
FCF growth 3Y35.74%
FCF growth 5Y-0.84%
OCF growth 1Y-8.6%
OCF growth 3Y19.98%
OCF growth 5Y2.13%

SURGERY PARTNERS INC / SGRY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SGRY.


What is the valuation status for SGRY stock?

ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.


Can you provide the profitability details for SURGERY PARTNERS INC?

SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.


What is the valuation of SURGERY PARTNERS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 31.02 and the Price/Book (PB) ratio is 1.08.


Can you provide the expected EPS growth for SGRY stock?

The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to decline by -46.78% in the next year.